Hospitals Sue Over Costly Lilly 340B Data Mandate
Hospitals face sharp drug price increases as manufacturers demand in-house claims data to maintain 340B discounts.
Updated on Oct. 21, 2026 in Healthcare
Live Poll
Should pharmaceutical companies be allowed to condition drug discounts on the submission of internal claims data?
Two hospitals have initiated lawsuits against Eli Lilly regarding its policy requiring covered entities to submit in-house claims data to maintain 340B drug discounts. The move, which began in February 2026, has already led to the suspension of discounted pricing for several providers, including Tampa General Hospital.
Why it matters
The dispute centers on Lilly's demand for data to combat alleged fraud and waste within the 340B program, which now dictates whether hospitals retain access to statutorily mandated pricing. For operators, this conflict signals a critical shift in procurement compliance as manufacturers leverage direct data demands to enforce purchasing conditions.
Eli Lilly reports that 2,350 organizations have submitted in-house claims data, representing 70% of covered entities. For those failing to comply, the impact is significant: Tampa General Hospital saw the unit price of Mounjaro jump from $750.52 to $1,019.74, a 35.9% increase.
The players
Eli Lilly
A global pharmaceutical company that develops and markets specialized drugs, including the diabetes medication Mounjaro.
Tampa General Hospital
A major Florida-based academic medical center currently challenging the legality of manufacturer-imposed claims data mandates.
Mary Hitchcock Memorial Hospital
A New Hampshire-based medical center that joined the litigation after losing access to 340B drug discounts.
Washington Legal Foundation
A nonprofit public interest law firm and policy center that filed an amicus brief supporting the manufacturer's position.
McKesson
A large-scale pharmaceutical wholesaler that serves as a primary distribution intermediary for hospital drug procurement.
The details
Lilly requires hospitals to submit proprietary claims data within five business days or face the termination of 340B pricing. The company executes this by directing wholesalers to discontinue discounts for non-compliant providers. Consequently, Tampa General Hospital projects an annual loss of $24.7 million due to these enforcement measures.
Timeline
February 2026: Lilly initiated its 340B data collection requirements for hospitals.
June 1, 2026: Lilly issued formal correspondence regarding its 340B data policy.
June 18, 2026: McKesson ceased providing 340B discounts to Tampa General Hospital.
July 2, 2026: Tampa General Hospital filed suit against Lilly and Lilly USA.
September 22, 2026: The Washington Legal Foundation submitted an amicus brief.
Market Landscape
This litigation highlights the growing friction between pharmaceutical manufacturers and hospitals over the administration of the federal 340B drug pricing program. It follows a pattern set by other manufacturers, such as Novo Nordisk, which implemented similar claims data requirements on April 1, 2026.
Hospital operators should audit their current 340B data submission workflows to ensure compliance with manufacturer-specific demands to avoid sudden price spikes. Financial teams must model the impact of a total loss of 340B discounts on high-cost specialty drugs like Mounjaro to prepare for potential procurement disruptions.
The takeaway
The dispute underscores the need for operators to monitor manufacturer communications regarding 340B eligibility. Administrators should track the progress of the pending U.S. District Court cases, as the judicial outcome will set a precedent for the enforceability of manufacturer data demands.
Further reading
For broader trends affecting supply chain costs, visit the Healthcare section.
Source note: This article includes information reported by Becker's Hospital Review | Healthcare News & Analysis.
Live Poll
Should pharmaceutical companies be allowed to condition drug discounts on the submission of internal claims data?
